Vanderbilt receives $1M grant to fund immunotherapy research in CRC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Robert J. Kleberg Jr. and Helen C. Kleberg Foundation awarded a $1 million grant to support research at Vanderbilt aimed at dramatically expanding the efficacy of immunotherapy for colorectal cancer. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Piktor, an investigational all-oral combination of serabelisib and sapanisertib, given with paclitaxel to patients with advanced endometrioid endometrial cancer and a PI3K/AKT/mTOR pathway mutation who had received at least one prior line of therapy, yielded a 33% confirmed objective response rate in efficacy-evaluable patients, and a disease control rate of 83%, according to clinical data from phase II trial (FTH-PIK-201; NCT06463028; GOG-311). 
Scientists at the Wistar Institute have identified a combination treatment that overcomes two of the biggest barriers to immunotherapy in glioblastoma. The researchers showed that reprogramming myeloid cells, a type of immune cell that glioblastoma tumors co-opt to protect themselves, while simultaneously boosting cancer-fighting T cells shrank the tumors and prevented them from coming back.
A study from researchers at ChristianaCare’s Helen F. Graham Cancer Center & Research Institute identifies a potential way to make colorectal cancer more responsive to retinoids, compounds related to vitamin A that can help regulate how cells grow and mature. The article “Inhibition of WNT signaling sensitizes CRC cells to anti-tumor effects of retinoids: Basis for new drug combinations in oncology,” 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login